Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Completed
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/06/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
Completed
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.
Gender:
FEMALE
Ages:
Between 6 years and 12 years
Trial Updated:
05/23/2024
Locations: University of Alabama Birmingham School of Medicine, Birmingham, Alabama +6 locations
Conditions: Rett Syndrome
The Effects of Low Dose Ketamine on Cardiovascular Function
Terminated
Low dose ketamine is used for pain management and for the treatment of anxiety and depression. Prior studies on low dose ketamine have noted short-term (minutes to hours) increases or decreases in blood pressure. Blood pressure that is too high or too low can be problematic if untreated. It is unknown exactly how low dose ketamine affects blood pressure. In fact, no prior studies have measured sympathetic nervous system activity after low dose ketamine has been given to an adult. Because sympath... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/20/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Healthy
Low Dose Ketamine for Blunt Thoracic Trauma
Completed
The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) decreases narcotic use • does LDKI impact pulmonary complications, readmission, or hospital length of stay Participants will receive usual standard of care with up to 48 hours of LDKI or placebo. If th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: North Memorial Health Hospital, Robbinsdale, Minnesota
Conditions: Blunt Injury of Thorax, Multiple Rib Fractures, Involving Three Ribs
Ketamine for OUD and Suicidal Ideation in the ED
Recruiting
This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate the safety of the ketamine treatment. The secondary aim is to determine the preliminary efficacy of opioid- and suicide-related outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder, Suicidal Ideation
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
Completed
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration. Standard safety, pharmacokinetics (PK) and qEEG monitoring will be evaluated at all dose levels. Subsequently, a 2-cohort multiple ascending dose (MAD) study will be conducted. Doses will be administered on days 1, 4, 8, and 11. Standard safety parameters will be monitored, and PK will be evaluated at all dose levels. Finally, a single-cohort gr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2024
Locations: Duke Early Phase Clinical Research, Durham, North Carolina
Conditions: Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
Completed
This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks \[Day -15 to Day -2\]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment \[Day 1\]), and post-treatment follow-up (7 and 14 days after infusion on Days 8 and 15, respectively). A total of 93 adult subjects with TRD will be randomly allocated in equal cohorts of 31 subjects/arm to the 3 arms of the study in a blinded manner.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2024
Locations: Preferred Research Partners, Little Rock, Arkansas +20 locations
Conditions: Treatment Resistant Depression
Prevention of Post Mastectomy With Intraoperative Ketamine
Active Not Recruiting
Aim 1: To determine the effectiveness of perioperatively administered ketamine to decrease acute and persistent postmastectomy pain (PPMP). Hypothesis 1.1: Patients undergoing partial or total mastectomy treated with a bolus and perioperative infusion of the NMDA-receptor antagonist ketamine will have decreased postoperative pain and opioid utilization compared to those receiving saline control. Hypothesis 1.2: Patients undergoing partial or total mastectomy treated with a bolus and perioperat... Read More
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
05/02/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
Completed
About one-third of depressed patients will not get better after multiple antidepressant treatments. This situation put a high burden on patients with depression due to worsening quality of life and increasing health care costs. Difficult-to-treat depression might be even worse among Veterans given that the frequency of depressive symptoms is 2 to 5 times higher than among the general US population. A breakthrough discovery happened in recent years when investigators found that one infusion from... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Treatment-resistant Depression
KAP for Depression in Abstinent Opioid Users
Terminated
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks o... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/10/2024
Locations: Medical University of South Carolina Centerspace, Charleston, South Carolina
Conditions: Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
Pain Medicine for Wound Care Procedures
Completed
This is a randomized double-blind study to determine if the administration of a small-dose of ketamine (an anesthetic)added to morphine (an opioid) contributes to reducing pain intensity during open wound care procedure (WCP)in patients who have had a traumatic injury and are in an Intensive Care Unit. Patients will be randomized to receive morphine plus saline (a placebo) or morphine plus ketamine before the WCP. The second time the patient is scheduled for WCP (no less than 24 hours), patients... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/25/2024
Locations: University of California San Francisco, San Francisco, California +1 locations
Conditions: Wound Care, Pain Intensity, Hyperalgesia, Nausea, Vomiting, Hallucinations
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
Completed
The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/21/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Cannabis, Ketamine